Taken together, our results indicate that Mo-DCs from LCH patients display an increased survival rate correlated with IL-17A and BCL2A1 expression, suggesting that BCL2A1 increases DC survival and participates in the accumulation of viable LCH-DCs within lesions. The gene discussed is IL17A; the disease is Langerhans cell histiocytosis.